India has taken a major step forward in diabetes and obesity care with the launch of Mounjaro (tirzepatide), a revolutionary once-weekly injectable drug developed by Eli Lilly. Already hailed internationally as a game-changing medication for type 2 diabetes and significant weight loss, Mounjaro's entry into the Indian pharmaceutical market is set to benefit millions struggling with chronic metabolic conditions.
With India ranking among the top countries affected by type 2 diabetes and obesity, the availability of Mounjaro brings hope for better long-term disease management.
What is Mounjaro?
Mounjaro contains tirzepatide, a novel dual incretin mimetic that targets two key hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones help regulate blood sugar levels, improve insulin sensitivity, and control appetite.
Unlike earlier GLP-1-based drugs like Ozempic or Victoza, Mounjaro uniquely activates both GLP-1 and GIP receptors, offering superior outcomes for blood sugar control and weight reduction.
Initially approved by the US FDA in 2022 for type 2 diabetes, Mounjaro has also gained attention globally for its off-label success in obesity and weight loss. In India, it has been approved specifically for managing type 2 diabetes in adults.
Mounjaro Launch in India
Eli Lilly officially launched Mounjaro in India in early March 2025, following approval by the Drugs Controller General of India (DCGI). The introduction aligns with a growing demand for advanced diabetes therapies that offer not only glycemic control but also address the rising challenge of obesity-linked metabolic disorders.
The drug is now available in major Indian cities through leading hospital pharmacies, specialty clinics, and select online health platforms.
Pricing of Mounjaro in India
Pharma giant Eli Lilly has launched Mounjaro in India with a focus on treating both type 2 diabetes and obesity . Contrary to earlier global price expectations, the Indian rollout comes at a much more accessible price point, making it a significant move in expanding the drug’s reach.
As of March 2025, here are the official retail prices:
Dose |
Price (INR) |
|---|---|
2.5 mg (starter dose) |
₹3,500 |
5 mg |
₹4,375 |
Each pack contains one prefilled pen, delivering a single once-weekly subcutaneous injection. Higher doses (7.5 mg, 10 mg, etc.) are expected to roll out in later phases of the launch.
Mounjaro is available only via prescription and must be obtained from authorized pharmacies. The relatively affordable pricing in India is expected to increase accessibility for patients who previously found advanced injectables cost-prohibitive.
How to Get Mounjaro in India
Mounjaro is a prescription-only medication, meaning it cannot be purchased over the counter. Here's how to obtain it:
Step-by-Step Access:
Consult a Diabetologist or Endocrinologist
Mounjaro should be prescribed only after a full assessment of blood sugar levels, BMI, and overall health profile. It’s especially useful for patients who haven’t responded well to other oral anti-diabetics or injectables.Get Your Prescription
Your doctor will initiate treatment with a 2.5 mg dose and guide the dosage escalation based on tolerance and response.Order from a Trusted Pharmacy
With the prescription in hand, you can place your order through a hospital pharmacy or verified online provider. Cold chain storage is essential—ensure it’s delivered in temperature-controlled packaging.
Who Should Use Mounjaro?
In India, Mounjaro is approved for adults with type 2 diabetes mellitus, particularly those:
Struggling with poor glycemic control despite oral medications
With high insulin resistance
Also dealing with overweight or obesity
Precautions and Side Effects
Like all GLP-1-based drugs, Mounjaro can cause gastrointestinal side effects, especially in the initial weeks of treatment. Common symptoms include:
Nausea
Vomiting
Diarrhea
Constipation
Mild abdominal pain
These usually subside with time or dose adjustment. Rare but serious risks include pancreatitis, gallbladder issues, or thyroid tumors—hence, regular follow-ups are important.
Not recommended for:
Type 1 diabetics
Pregnant or breastfeeding women
People with a history of medullary thyroid cancer or MEN-2 syndrome
Comparison with Other Medications in India
Drug |
Use |
Weight Loss Effect |
Dose Type |
Weekly Dosing |
|---|---|---|---|---|
Mounjaro |
Type 2 diabetes (India) |
High (15–22%) |
Injectable pen |
Yes |
Ozempic |
Not launched in India |
Moderate (10–15%) |
Injectable pen |
Yes |
Trulicity |
Type 2 diabetes |
Mild (2–5%) |
Injectable pen |
Yes |
Metformin |
First-line diabetes drug |
Minimal (<2%) |
Oral tablet |
Daily |
Mounjaro clearly stands out for its weight loss benefits and dual hormone action, making it a preferred choice for eligible patients.
Ozempic is not yet officially launched in India but its alternatives like GLP-1 can be accessed through platforms like Elevate Now after checking your eligibility.
How Elevate Now is Revolutionizing Weight Loss
- Elevate Now is India’s first doctor-led medical weight loss program, designed to tackle the root causes of weight gain and improve metabolic health for sustainable results.
The program offers comprehensive diagnosis through 80+ specialized blood tests that assess hormonal, inflammatory, and metabolic markers, with at-home sample collection via NABL-accredited labs for convenience. - A team of M.D. doctors, led by Dr. Neeta Deshpande, India’s leading obesity expert, provides expert medical guidance, ensuring safe and effective weight management. Elevate Now also offers personalized weight loss medications, including GLP-1 protocols tailored to the Indian population, along with appetite suppressants, fat blockers, and diabetes-specific treatments.
- Beyond medications, the program includes certified human coaches who create customized nutrition, fitness, sleep, and stress management plans, adapting to regional diets and languages. With a results-driven and affordable approach, Elevate Now ensures that clients pay only for necessary interventions, making it a scientific, sustainable, and long-term solution for weight loss.
(Check your eligibility here)
Summary
With its launch in India, Mounjaro introduces a powerful new tool in the fight against type 2 diabetes and offers hope for patients struggling with obesity-related health challenges. Though priced at a premium, its clinical benefits—ranging from improved glycemic control to significant weight loss—make it a valuable option for many.
Now available across India’s top cities and pharmacies, Mounjaro must be prescribed by a qualified doctor and taken under medical supervision. As awareness grows and accessibility improves, Mounjaro has the potential to reshape the treatment landscape for diabetes and obesity in India.
